NCT01689220已完成1 期
A Phase 1 Study of SP-02L (Darinaparsin for Injection) in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) in Korea
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 6
- 试验地点
- 1
- 主要终点
- Incidence of dose-limiting toxicity and adverse events
研究概览
简要总结
The purpose of this study is to evaluate the safety and tolerability of SP-02L monotherapy in Korean patients with relapsed or refractory Peripheral T-cell Lymphoma (PTCL).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Korean patients aged ≥ 20 years of age at the day of obtaining the informed consent
- •Patients with histologically confirmed diagnosis of the following:
- •PTCL, not otherwise specified (PTCL-NOS)
- •Anaplastic Large Cell Lymphoma (ALCL ALK-positive/negative)
- •Angioimmunoblastic T-cell Lymphoma (AITL)
- •Have relapsed or refractory to at least one prior systemic chemotherapy for the above disease (currently requiring therapy)
- •Have at least 1 evaluable lesion
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
- •Life expectancy of at least 3 months
排除标准
- 未提供
研究组 & 干预措施
SP-02L
Experimental
干预措施: SP-02L (darinaparsin for injection) (Drug)
结局指标
主要结局
Incidence of dose-limiting toxicity and adverse events
时间窗: 12 or 16 weeks
次要结局
- Plasma concentration-time profile(0, 0.5, 1, 2, 4, 8 hours post-dose on Day 1 and 5, and 0 hour on Day 2, 3, 4, 6, 8 and 15)
- Tumor response (overall response)(2 and 4 cycles)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL)Peripheral T-cell LymphomaNCT01435863Solasia Pharma K.K.17
已完成
2 期
Efficacy and Safety Study of Panobinostat in Participants With Metastatic Hormone Refractory Prostate CancerProstate CancerNCT00667862Novartis Pharmaceuticals35
已完成
1 期
A Phase 1 Study of IS-002 Injection in Patients Undergoing Robotic ProstatectomyProstate CancerNCT04574401Intuitive Surgical24
进行中（未招募）
1 期
A Gene Transfer Study for Late-Onset Pompe Disease (RESOLUTE)Lysosomal Storage DiseasesPompe Disease (Late-onset)Glycogen Storage Disease Type 2Glycogen Storage Disease Type IILOPDAcid Maltase DeficiencyPompe DiseaseNCT04093349Spark Therapeutics, Inc.4
招募中
2 期
A Single-Dose Study to Evaluate Safety and Efficacy of CS-1103 in Participants Receiving a Single Dose of MethamphetamineMethamphetamine IntoxicationMethamphetamine DisordersMethamphetamine AbuseNCT06721494Clear Scientific, Inc.40